However, biotech remains high risk. Even promising clinical results do not guarantee approval or share-price gains. For $Trevi Therapeutics, Inc.(TRVI)$ and CMPS, I would prefer to see stronger clinical and commercialization evidence before becoming too optimistic. Analyst price targets are useful references, not guaranteed returns.
Overall, I would keep position sizes small and avoid concentrating too much capital in one biotech stock. For me, the best opportunity is not the highest price target, but the company with the strongest balance of clinical progress, financial strength, upcoming catalysts and valuation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- HunterGame·10-20 16:43TOPBLTE's 2027 FDA date is the hook, but discounting that back today still needs a real peak sales case. PTCT having actual revenue just makes the risk/reward cleaner1Report